CicloprololAlternative Names: SL 75177; SL 75177 10; SLD 177
Latest Information Update: 14 May 1997
At a glance
- Originator Sanofi-Synthelabo
- Mechanism of Action Beta 1 adrenergic receptor agonists; Beta 2 adrenergic receptor antagonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Heart failure; Hypertension; Ischaemic heart disorders
Most Recent Events
- 14 May 1997 Discontinued-preregistration for Heart failure in France (Unknown route)